151751-Najiba-Chargi

301 Systemic therapy: skeletal muscle mass and oropharyngeal carcinoma Table 1. (Continued) Variables Low SMM N=140 Without low SMM N=76 χ 2 p-value Localization (n, %) Tonsil Base of tongue Soft palate Oropharynx n.o.s 33 6 7 84 23.6 11.4 5 60 24 6 3 43 31.6 7.9 3.9 56.6 2.02 0.57 Tumor stage (n, %) T1 T2 T3 T4a T4b 30 52 26 25 7 21.4 37.1 18.6 17.9 5 16 31 15 13 1 21.1 40.8 19.7 17.1 1.3 2.03 0.74 Nodal stage (n, %) N0 N1 N2a N2b N2c N3 66 23 4 28 16 3 47.1 16.4 2.9 20 11.4 2.1 24 15 6 23 8 0 31.6 19.7 7.9 30.3 10.5 0 9.73 0.08 TNM stage (n, %) I II III IV 20 29 26 65 14.3 20.7 18.6 46.4 7 14 12 43 9.2 18.4 15.8 56.6 2.38 0.51 Chemotherapy (n, %) No Primary Adjuvant 95 40 5 67.9 28.6 3.6 41 33 2 53.9 43.4 2.6 4.86 0.09 Radiotherapy (n, %) No Primary Adjuvant 18 113 9 12.9 80.7 6.4 5 64 7 6.6 84.2 9.2 2.41 0.29 Surgery (n, %) No Yes 110 30 78.6 21.4 61 15 80.3 19.7 0.06 0.86 Legend: **. Correlation is significant at the 0.01 level (2-tailed), *. Correlation is significant at the 0.05 level (2-tailed), NA. Not applicable Figure 1. shows the Kaplan Meier survival curves and number at risk tables of overall and disease-free survival for OPSCC patients with and without low SMM. Patients with low SMM had a significant lower median OS (32.74; IQR 12.72-53.70) compared to patients without low SMM (42.05; IQR 23.61-62.32) (Log rank χ 2= 4.30; p=0.04) with a 5-year OS rate of 43% versus 66%. Patients with low SMM showed a statistical trend towards lower median DFS rate (24.72 months; IQR 9.42-51.78) compared to patients without low SMM (35.25 months; IQR 15.93- 62.10) (Log rank χ 2=3.35, p=0.07) with a 5-year DFS rate of 61% versus 76%. 16